Updates

Nasopharyngeal Carcinoma

12/03/2015 Conditions

min. read

Topics

About nasopharyngeal carcinoma in children

Nasopharyngeal carcinoma is a rare cancer that arises in the upper part of the throat behind the nose. It is associated with Epstein Barr Virus infection in children. Children usually present with advanced stage disease with involvement of the lymph glands in the neck. We treat children with nasopharyngeal carcinoma with combination of chemotherapy and radiation therapy.

Research

Researchers at Texas Children's Cancer Center are undertaking a ground breaking clinical trial to train patient's own immune system to kill nasopharyngeal cancer cells. More information on this research can be found here. In order to further the understanding of nasopharyngeal cancer in children and improve their outcomes, we have established the North American Pediatric Nasopharyngeal Carcinoma Registry. Email us at raretumors@texaschildrens.org to get information on how to enroll in the registry.

Second opinions

We welcome oncologists to contact us for second opinion consultations about the care and management of individual patients.

Publications

Chia, Whay-Kuang, Marissa Teo, Who-Whong Wang, Bernett Lee, Soo-Fan Ang, Wai-Meng Tai, Chit-Lai Chee, et al. “Adoptive T-Cell Transfer and Chemotherapy in the First-Line Treatment of Metastatic And/or Locally Recurrent Nasopharyngeal Carcinoma.” Molecular Therapy: The Journal of the American Society of Gene Therapy 22, no. 1 (January 2014): 132–39. doi:10.1038/mt.2013.242.

Chia, W. K., W.-W. Wang, M. Teo, W. M. Tai, W. T. Lim, E. H. Tan, S. S. Leong, et al. “A Phase II Study Evaluating the Safety and Efficacy of an Adenovirus-ΔLMP1-LMP2 Transduced Dendritic Cell Vaccine in Patients with Advanced Metastatic Nasopharyngeal Carcinoma.” Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO 23, no. 4 (April 2012): 997–1005. doi:10.1093/annonc/mdr341.

Gottschalk, S., C. M. Bollard, K. C. Straathof, C. U. Louis, B. Savoldo, G. Dotti, M. K. Brenner, H. E. Heslop, and C. M. Rooney. “T Cell Therapies.” Ernst Schering Foundation Symposium Proceedings, no. 4 (2006): 69–82.

Gottschalk, Stephen, Helen E. Heslop, and Cliona M. Roon. “Treatment of Epstein-Barr Virus-Associated Malignancies with Specific T Cells.” Advances in Cancer Research 84 (2002): 175–201.

Gottschalk, Stephen, Helen E. Heslop, and Cliona M. Rooney. “Adoptive Immunotherapy for EBV-Associated Malignancies.” Leukemia & Lymphoma 46, no. 1 (January 2005): 1–10. doi:10.1080/10428190400002202.

Gottschalk, Stephen, and Cliona M. Rooney. “Adoptive T-Cell Immunotherapy.” Current Topics in Microbiology and Immunology 391 (2015): 427–54. doi:10.1007/978-3-319-22834-1_15.

Louis, Chrystal U., Arnold C. Paulino, Stephen Gottschalk, Allison A. Bertuch, Murali Chintagumpala, Helen E. Heslop, and Heidi V. Russell. “A Single Institution Experience with Pediatric Nasopharyngeal Carcinoma: High Incidence of Toxicity Associated with Platinum-Based Chemotherapy plus IMRT.” Journal of Pediatric Hematology/Oncology 29, no. 7 (July 2007): 500–505. doi:10.1097/MPH.0b013e3180959af4.

Louis, Chrystal U., Karin Straathof, Catherine M. Bollard, Sravya Ennamuri, Claudia Gerken, Teresita T. Lopez, M. Helen Huls, et al. “Adoptive Transfer of EBV-Specific T Cells Results in Sustained Clinical Responses in Patients with Locoregional Nasopharyngeal Carcinoma.” Journal of Immunotherapy (Hagerstown, Md.: 1997) 33, no. 9 (December 2010): 983–90. doi:10.1097/CJI.0b013e3181f3cbf4.

Louis, Chrystal U., Karin Straathof, Catherine M. Bollard, Claudia Gerken, M. Helen Huls, M. Victoria Gresik, Meng-Fen Wu, et al. “Enhancing the in Vivo Expansion of Adoptively Transferred EBV-Specific CTL with Lymphodepleting CD45 Monoclonal Antibodies in NPC Patients.” Blood 113, no. 11 (March 12, 2009): 2442–50. doi:10.1182/blood-2008-05-157222.

Ngo, Minhtran Charlotte, Jun Ando, Ann M. Leen, Sravya Ennamuri, Natalia Lapteva, Juan F. Vera, Amelia Min-Venditti, et al. “Complementation of Antigen-Presenting Cells to Generate T Lymphocytes with Broad Target Specificity.” Journal of Immunotherapy (Hagerstown, Md.: 1997) 37, no. 4 (May 2014): 193–203. doi:10.1097/CJI.0000000000000014